Skip to content Skip to navigation

Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients

TitleImpact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients
Publication TypeJournal Article
Year of Publication2012
AuthorsKaya, H, Peressini, B, Jawed, I, Martincic, D, Elaimy, AL, Lamoreaux, WT, Fairbanks, RK, Weeks, KA, Lee, CM
JournalInternational Journal of HematologyInternational Journal of Hematology
Volume95
Pagination64-70
Date PublishedJan
ISBN Number0925-5710
Accession NumberWOS:000300508800011
KeywordsAsian/Pacific, bortezomib, chemotherapy, clinical-trial, Islander, lenalidomide plus dexamethasone, leukemia, long-term survival, Multiple myeloma, natives, Overall survival, Population analysis, prednisone, Race, SEER, thalidomide
AbstractWith the availability of novel agents, the overall survival (OS) in patients diagnosed with multiple myeloma (MM) has improved over the last decade. Data on 40,294 MM patients in the years from 1973 to 2003 were obtained from the Surveillance, Epidemiology, and End Results Program (SEER) of the US National Cancer Institute. Statistical analyses evaluating gender, race, age, and year of diagnosis were performed using univariate and multivariate Cox regression models for the OS endpoint. The mean patient age at diagnosis was 68.3 years. Mean survival was 30 months (median = 19 months). Asian/Pacific Islander race was associated with an improved OS, HR 0.90 (CI 0.86-0.95, P